BACKGROUND: Adipose tissue represents an abundant and easily accessible source of multipotent cells that may serve as an excellent building block for tissue engineering. However, adipose-derived stromal cells (ASCs) are a heterogeneous group and subpopulations may be identified with enhanced osteogenic potential. METHODS: Human ASC subpopulations were prospectively isolated based on expression of bone morphogenetic protein receptor type-IB (BMPR-IB). Unsorted, BMPR-IB(+), and BMPR-IB(-) cells were analyzed for their osteogenic capacity through histological staining and gene expression. To evaluate their in vivo osteogenic potential, critical-sized calvarial defects were created in immunocompromised mice and treated with unsorted, BMPR-IB(+), or BMPR-IB(-) cells. Healing was assessed using microcomputed tomography and pentachrome staining of specimens at 8 weeks. RESULTS: Increased osteogenic differentiation was noted in the BMPR-IB(+) subpopulation, as demonstrated by alkaline phosphatase staining at day 7 and extracellular matrix mineralization with Alizarin red staining at day 14. This was also associated with increased expression for osteocalcin, a late marker of osteogenesis. Radiographic analysis demonstrated significantly enhanced healing of critical-sized calvarial defects treated with BMPR-IB(+) ASCs compared with unsorted or BMPR-IB(-) cells. This was confirmed through pentachrome staining, which revealed more robust bone regeneration in the BMPR-IB(+) group. CONCLUSION: BMPR-IB(+) human ASCs have an enhanced ability to form bone both in vitro and in vivo. These data suggest that positive selection for BMPR-IB(+) and manipulation of the BMP pathway in these cells may yield a highly osteogenic subpopulation of cells for bone tissue engineering.
BACKGROUND: Adipose tissue represents an abundant and easily accessible source of multipotent cells that may serve as an excellent building block for tissue engineering. However, adipose-derived stromal cells (ASCs) are a heterogeneous group and subpopulations may be identified with enhanced osteogenic potential. METHODS:Human ASC subpopulations were prospectively isolated based on expression of bone morphogenetic protein receptor type-IB (BMPR-IB). Unsorted, BMPR-IB(+), and BMPR-IB(-) cells were analyzed for their osteogenic capacity through histological staining and gene expression. To evaluate their in vivo osteogenic potential, critical-sized calvarial defects were created in immunocompromised mice and treated with unsorted, BMPR-IB(+), or BMPR-IB(-) cells. Healing was assessed using microcomputed tomography and pentachrome staining of specimens at 8 weeks. RESULTS: Increased osteogenic differentiation was noted in the BMPR-IB(+) subpopulation, as demonstrated by alkaline phosphatase staining at day 7 and extracellular matrix mineralization with Alizarin red staining at day 14. This was also associated with increased expression for osteocalcin, a late marker of osteogenesis. Radiographic analysis demonstrated significantly enhanced healing of critical-sized calvarial defects treated with BMPR-IB(+) ASCs compared with unsorted or BMPR-IB(-) cells. This was confirmed through pentachrome staining, which revealed more robust bone regeneration in the BMPR-IB(+) group. CONCLUSION:BMPR-IB(+) human ASCs have an enhanced ability to form bone both in vitro and in vivo. These data suggest that positive selection for BMPR-IB(+) and manipulation of the BMP pathway in these cells may yield a highly osteogenic subpopulation of cells for bone tissue engineering.
Authors: R Quarto; M Mastrogiacomo; R Cancedda; S M Kutepov; V Mukhachev; A Lavroukov; E Kon; M Marcacci Journal: N Engl J Med Date: 2001-02-01 Impact factor: 91.245
Authors: M J Wissink; R Beernink; A A Poot; G H Engbers; T Beugeling; W G van Aken; J Feijen Journal: J Control Release Date: 2000-02-14 Impact factor: 9.776
Authors: Byeong S Yoon; Dmitry A Ovchinnikov; Isaac Yoshii; Yuji Mishina; Richard R Behringer; Karen M Lyons Journal: Proc Natl Acad Sci U S A Date: 2005-03-21 Impact factor: 11.205
Authors: Michael T Chung; Chunjun Liu; Jeong S Hyun; David D Lo; Daniel T Montoro; Masakazu Hasegawa; Shuli Li; Michael Sorkin; Robert Rennert; Michael Keeney; Fan Yang; Natalina Quarto; Michael T Longaker; Derrick C Wan Journal: Tissue Eng Part A Date: 2013-01-28 Impact factor: 3.845
Authors: D Chen; X Ji; M A Harris; J Q Feng; G Karsenty; A J Celeste; V Rosen; G R Mundy; S E Harris Journal: J Cell Biol Date: 1998-07-13 Impact factor: 10.539
Authors: Elizabeth Brett; Natalie Chung; William Tripp Leavitt; Arash Momeni; Michael T Longaker; Derrick C Wan Journal: Tissue Eng Part B Rev Date: 2017-04-27 Impact factor: 6.389
Authors: Clement D Marshall; Elizabeth R Zielins; Elizabeth A Brett; Charles P Blackshear; Michael S Hu; Tripp Leavitt; Leandra A Barnes; H Peter Lorenz; Michael T Longaker; Derrick C Wan Journal: J Vis Exp Date: 2017-02-24 Impact factor: 1.355
Authors: Aaron W James; Gregory LaChaud; Jia Shen; Greg Asatrian; Vi Nguyen; Xinli Zhang; Kang Ting; Chia Soo Journal: Tissue Eng Part B Rev Date: 2016-04-19 Impact factor: 6.389
Authors: Elizabeth Brett; Elizabeth R Zielins; Monica Chin; Michael Januszyk; Charles P Blackshear; Michael Findlay; Arash Momeni; Geoffrey C Gurtner; Michael T Longaker; Derrick C Wan Journal: Wound Repair Regen Date: 2017-05-18 Impact factor: 3.617
Authors: Elizabeth R Zielins; Kevin Paik; Ryan C Ransom; Elizabeth A Brett; Charles P Blackshear; Anna Luan; Graham G Walmsley; David A Atashroo; Kshemendra Senarath-Yapa; Arash Momeni; Robert Rennert; Michael Sorkin; Eun Young Seo; Charles K Chan; Geoffrey C Gurtner; Michael T Longaker; Derrick C Wan Journal: Tissue Eng Part A Date: 2016-01-27 Impact factor: 3.845
Authors: Ruth Tevlin; Adrian McArdle; Elizabeth Brett; Michael T Chung; Kevin Paik; Eun Young Seo; Graham G Walmsley; Christopher R Duldulao; David Atashroo; Elizabeth Zielins; Stephanie Vistnes; Charles K F Chan; Derrick C Wan; Michael T Longaker Journal: Plast Reconstr Surg Date: 2016-12 Impact factor: 4.730